News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

HIV franchise remains its biggest value driver. The firm believes a strong launch of lenacapavir in pre-exposure ...

Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated a Buy ...

Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash ...

March 11, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s ...

Gilead Sciences’ already dominant position in ... and showed a subcutaneous injection with lenacapavir every six months was more effective than its widely-used oral PrEP drug Truvada ...

Gilead Sciences, Inc. (NASDAQ:GILD) has unveiled new data from its HIV treatment research at the 25th... “ PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir ...

Gilead Sciences, Inc. (Nasdaq: NASDAQ:GILD) today announced data evaluating lenacapavir in combination with broadly neutralizing... Christi Shaw is leaving Gilead Sciences (NASDAQ:GILD ...

Gilead Sciences has taken a major step towards increasing ... paving the way for increased production and distribution of lenacapavir, its long-acting HIV prevention medication, in 120 high ...

Citigroup said it’s “very bullish” on Gilead’s HIV franchise, arguing it’s the drugmaker’s biggest value driver as the company’s new ...

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...